Rose 11%, with energy vertical revenue more than doubling for the second consecutive quarter; segment profit margin down 370 basis points due to prior-year reserve credits not recurring and ...
CRISPR Therapeutics' CASGEVY gene-editing therapy targets severe SCD and TDT. Click here to read why CRSP stock is rated as a Buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results